A randomized open-label study of 3-versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 66, Issue 2, 2014, Pages 140-147

  Markowitz, Martin ^a   Evering, Teresa H ^a   Garmon, Donald ^a   Caskey, Marina ^a   La Mar, Melissa ^a   Rodriguez, Kristina ^a   Sahi, Vincent ^a   Palmer, Sarah ^b,c   Prada, Nicole ^a   Mohri, Hiroshi ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

intensified cART recent HIV 1 infection

Indexed keywords

ATAZANAVIR; DARUNAVIR; EMTRICITABINE; MARAVIROC; RALTEGRAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR DIFUMARATE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DNA, VIRAL; DRUG COMBINATIONS; ENDPOINT DETERMINATION; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PYRROLIDINONES; RNA, VIRAL; TRIAZOLES; VIRAL LOAD; VIREMIA;

EID: 84901502098     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000111     Document Type: Conference Paper

References (29)

1. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. (Pubitemid 44306484)
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860. (Pubitemid 28135961)
3. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.
4. Davey RT Jr, Bhat N, Yoder C, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A. 1999;96:15109-15114. (Pubitemid 30019773)
5. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:527-537. (Pubitemid 30016135)
6. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105:3879-3884. (Pubitemid 351723493)
7. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517. (Pubitemid 29220209)
8. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300. (Pubitemid 27495742)
9. Hunt JS, Romanelli F. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy. 2009;29:295-304.
10. Evering TH, Markowitz M. Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc). 2007;43:865-877. (Pubitemid 351160482)
11. Evering TH, Markowitz M. Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs. 2008;17:413-422. (Pubitemid 351578192)
12. Kothe D, Byers RH, Caudill SP, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr. 2003;33:625-634. (Pubitemid 36975851)
13. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003; 41:4531-4536. (Pubitemid 37259753)
14. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986;59:284-291. (Pubitemid 16013975)
15. Mohri H, Markowitz M. In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr. 2008;48:511-521.
16. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188. (Pubitemid 27209433)
17. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis. 2005;18:9-15. (Pubitemid 41716234)
18. McGovern RA, Thielen A, Mo T, et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS. 2010;24:2517-2525.
19. McGovern RA, Thielen A, Portsmouth S, et al. Population-based Sequencing of the V3-loop can predict the virological response to maraviroc in treatmentnaive patients of the MERIT trial. J Acquir Immune Defic Syndr. 2012.
20. Chow SC, Shao J, Wang H. Sample Size Calculations in Cilnical Research. New York, NY: Taylor and Francis; 2003.
21. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med. 2010;16:460-465.
22. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 2009;106:9403-9408.
23. Gandhi RT, Coombs RW, Chan ES, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;59:229-235.
24. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010;50:912-919.
25. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441-6457. (Pubitemid 43927447)
26. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
27. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr. 2013;62:505-508.
28. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012; 7:e33948.
29. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010; 24:2451-2460.